{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:16:50Z","timestamp":1788473810225,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001704","name":"European Society of Clinical Microbiology and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["PI24\/00739"],"award-info":[{"award-number":["PI24\/00739"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["ICI21\/00103"],"award-info":[{"award-number":["ICI21\/00103"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cmi.2026.08.019","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:07:53Z","timestamp":1786979273000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chimeric antigen receptor therapy in infectious diseases: emerging applications with a focus on invasive fungal infections"],"prefix":"10.1016","author":[{"given":"Carme","family":"Bracke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Grafia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Puerta-Alcalde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.08.019_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.28383","article-title":"A network for advancing prevention and treatment of infections among immunocompromised individuals","volume":"8","author":"Hill","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cmi.2026.08.019_bib2","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/S1473-3099(25)00345-7","article-title":"Innovation in active and passive immunisation of people who are immunocompromised: A call to action","volume":"26","author":"Hill","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.08.019_bib3","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","article-title":"Global incidence and mortality of severe fungal disease","volume":"24","author":"Denning","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.08.019_bib4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jinf.2023.05.005","article-title":"Breakthrough invasive fungal infection among patients with haematologic malignancies: A national, prospective, and multicentre study","volume":"87","author":"Puerta-Alcalde","year":"2023","journal-title":"J Infect"},{"key":"10.1016\/j.cmi.2026.08.019_bib5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jac\/dkx423","article-title":"Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: A post hoc analysis of the SECURE trial","volume":"73","author":"Kontoyiannis","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2026.08.019_bib6","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1016\/S1473-3099(17)30316-X","article-title":"The global problem of antifungal resistance: Prevalence, mechanisms, and management","volume":"17","author":"Perlin","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.08.019_bib7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/cid\/ciae203","article-title":"Breakthrough invasive fungal infections in patients with high-risk hematological disorders receiving voriconazole and posaconazole prophylaxis: A systematic review","volume":"79","author":"Boutin","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.08.019_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00074-23","article-title":"Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease","volume":"37","author":"Hoenigl","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2026.08.019_bib9","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/S1473-3099(17)30442-5","article-title":"Immunotherapeutic approaches to treatment of fungal diseases","volume":"17","author":"Armstrong-James","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.08.019_bib10","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.3389\/fimmu.2017.01939","article-title":"Methods of controlling invasive fungal infections using CD8+ T cells","volume":"8","author":"Kumaresan","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2026.08.019_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2024.110763","article-title":"A comprehensive review on the role of T cell subsets and CAR-T cell therapy in Aspergillus fumigatus infection","volume":"85","author":"Nasiri-Jahrodi","year":"2024","journal-title":"Hum Immunol"},{"key":"10.1016\/j.cmi.2026.08.019_bib12","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1182\/blood-2005-05-1775","article-title":"Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation","volume":"106","author":"Perruccio","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2026.08.019_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2325","article-title":"Therapeutic roles of CAR T cells in infectious diseases: Clinical lessons learnt from cancer","volume":"32","author":"Mohammadi","year":"2022","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.cmi.2026.08.019_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70306","article-title":"Diverse potential of chimeric antigen receptor-engineered cell therapy: Beyond cancer","volume":"15","author":"Wu","year":"2025","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.cmi.2026.08.019_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1289303","article-title":"CAR Immunotherapy for the treatment of infectious diseases: A systematic review","volume":"15","author":"Morte-Romea","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2026.08.019_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: Elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.cmi.2026.08.019_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1664403","article-title":"Non-signaling but all important: How the linker, hinge, and transmembrane domains in the CAR hold it all together","volume":"16","author":"Bernard","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2026.08.019_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1034707","article-title":"Next generations of CAR-T cells\u2014New therapeutic opportunities in hematology?","volume":"13","author":"Tomasik","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2026.08.019_bib19","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.scib.2025.01.002","article-title":"CAR-NK cell therapy: A potential antiviral platform","volume":"70","author":"Lin","year":"2025","journal-title":"Sci Bull (Beijing)"},{"key":"10.1016\/j.cmi.2026.08.019_bib20","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1182\/bloodadvances.2024014082","article-title":"CAR-NK cell therapy for hematological malignancies","volume":"10","author":"Manzar","year":"2026","journal-title":"Blood Adv"},{"key":"10.1016\/j.cmi.2026.08.019_bib21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jare.2025.01.004","article-title":"Exploring CAR-macrophages in non-tumor diseases: Therapeutic potential beyond cancer","volume":"77","author":"Chen","year":"2025","journal-title":"J Adv Res"},{"key":"10.1016\/j.cmi.2026.08.019_bib22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/jamaneurol.2024.3818","article-title":"Current and future roles of chimeric antigen receptor T-cell therapy in neurology: A review","volume":"82","author":"Ismail","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.cmi.2026.08.019_bib23","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: A translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2026.08.019_bib24","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/S2352-3026(24)00273-4","article-title":"Accelerating and optimising CAR T-cell manufacture to deliver better patient products","volume":"12","author":"Agliardi","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cmi.2026.08.019_bib25","first-page":"1823","article-title":"Optimizing in vivo CAR T-cell engineering for cancer immunotherapy","volume":"86","author":"Wang","year":"2026","journal-title":"Cancer Res"},{"key":"10.1016\/j.cmi.2026.08.019_bib26","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nri3897","article-title":"Immune defence against Candida fungal infections","volume":"15","author":"Netea","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cmi.2026.08.019_bib27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nri2939","article-title":"Immunity to fungal infections","volume":"11","author":"Romani","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cmi.2026.08.019_bib28","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.virol.2015.02.051","article-title":"PRRs are watching you: Localization of innate sensing and signaling regulators","volume":"479\u2013480","author":"Chow","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.cmi.2026.08.019_bib29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nrmicro.2015.21","article-title":"Interactions of fungal pathogens with phagocytes","volume":"14","author":"Erwig","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cmi.2026.08.019_bib30","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.4049\/jimmunol.168.3.1362","article-title":"Dendritic cells transport conidia and hyphae of Aspergillus fumigatus from the airways to the draining lymph nodes and initiate disparate Th responses to the fungus","volume":"168","author":"Bozza","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.cmi.2026.08.019_bib31","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nature04926","article-title":"Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity","volume":"442","author":"Gross","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2026.08.019_bib32","doi-asserted-by":"crossref","first-page":"10660","DOI":"10.1073\/pnas.1312789111","article-title":"Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection","volume":"111","author":"Kumaresan","year":"2014","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.cmi.2026.08.019_bib36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jcyt.2020.11.002","article-title":"Glucuronoxylomannan in the Cryptococcus species capsule as a target for chimeric antigen receptor T-cell therapy","volume":"23","author":"da Silva","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.cmi.2026.08.019_bib34","doi-asserted-by":"crossref","first-page":"eabh1209","DOI":"10.1126\/scitranslmed.abh1209","article-title":"CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models","volume":"14","author":"Seif","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cmi.2026.08.019_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03413-23","article-title":"A novel lentiviral vector-based approach to generate chimeric antigen receptor T cells targeting Aspergillus fumigatus","volume":"15","author":"Kumaresan","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.cmi.2026.08.019_bib37","doi-asserted-by":"crossref","DOI":"10.1080\/21655979.2025.2458786","article-title":"A novel mannan-specific chimeric antigen receptor M-CAR redirects T cells to interact with Candida spp. hyphae and Rhizopus oryzae spores","volume":"16","author":"Guimar\u00e3es","year":"2025","journal-title":"Bioengineered"},{"key":"10.1016\/j.cmi.2026.08.019_bib38","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.jcyt.2025.05.001","article-title":"Mannan-targeting chimeric antigen receptor redirected antifungal activity of NK-92 cells against Candida albicans","volume":"27","author":"de Campos","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.cmi.2026.08.019_bib35","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1016\/j.ymthe.2025.09.003","article-title":"Adoptive transfer of NK cells engineered with a CD5-based chimeric antigen receptor (SRCD5CAR) to treat invasive fungal infections","volume":"33","author":"Velasco-de-Andr\u00e9s","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.cmi.2026.08.019_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1772830","article-title":"Translational development and first-in-human compassionate infusion of NK-92 cells expressing a CD5-based chimeric antigen receptor (SRCD5CAR-NK-92) in a patient with multidrug-resistant fusariosis","volume":"17","author":"Velasco-de-Andr\u00e9s","year":"2026","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2026.08.019_bib40","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0065-2164(08)01005-8","article-title":"virulence in Cryptococcus species","volume":"67","author":"Ma","year":"2009","journal-title":"Adv Appl Microbiol"},{"key":"10.1016\/j.cmi.2026.08.019_bib41","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.4049\/jimmunol.155.2.1000","article-title":"Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes","volume":"155","author":"Tran","year":"1995","journal-title":"J Immunol."},{"key":"10.1016\/j.cmi.2026.08.019_bib42","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V96.3.785.015k10_785_793","article-title":"Prolonged survival and tissue trafficking following adoptive transfer of CD4\u03b6 gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus-infected subjects","volume":"96","author":"Mitsuyasu","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2026.08.019_bib43","first-page":"467","article-title":"Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection","volume":"96","author":"Walker","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2026.08.019_bib44","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1006\/mthe.2002.0611","article-title":"A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy","volume":"5","author":"Deeks","year":"2002","journal-title":"Mol Ther"},{"key":"10.1016\/j.cmi.2026.08.019_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006613","article-title":"Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor","volume":"13","author":"Leibman","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.cmi.2026.08.019_bib46","doi-asserted-by":"crossref","first-page":"eaav5685","DOI":"10.1126\/scitranslmed.aav5685","article-title":"Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model","volume":"11","author":"Anthony-Gonda","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cmi.2026.08.019_bib47","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150211","article-title":"Broadly neutralizing antibody-derived CAR T cells reduce viral reservoir in individuals infected with HIV-1","volume":"131","author":"Liu","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cmi.2026.08.019_bib48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41421-024-00658-z","article-title":"Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: A phase I, multicenter, single-arm, open-label study","volume":"10","author":"Mao","year":"2024","journal-title":"Cell Discov"},{"key":"10.1016\/j.cmi.2026.08.019_bib49","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3390\/v17121615","article-title":"CAR-T cell therapy for HIV cure: Current challenges, advances and future directions","volume":"17","author":"Padurariu-Covit","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.cmi.2026.08.019_bib50","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/infdis\/jiaa171","article-title":"Chimeric antigen receptors targeting human cytomegalovirus","volume":"222","author":"Ali","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2026.08.019_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000736","article-title":"CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B\u221735 control Epstein-Barr virus-associated lymphoproliferation","volume":"8","author":"Dragon","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.cmi.2026.08.019_bib52","article-title":"GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2026.08.019_bib53","doi-asserted-by":"crossref","first-page":"468","DOI":"10.7555\/JBR.28.20140066","article-title":"T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo","volume":"28","author":"Tang","year":"2014","journal-title":"J Biomed Res"},{"key":"10.1016\/j.cmi.2026.08.019_bib54","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1038\/s41467-022-30216-8","article-title":"Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19","volume":"13","author":"Lu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.cmi.2026.08.019_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116066","article-title":"Developing CAR-immune cell therapy against SARS-CoV-2: Current status, challenges and prospects","volume":"222","author":"Chen","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.cmi.2026.08.019_bib56","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2013.04.047","article-title":"T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice","volume":"145","author":"Krebs","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2026.08.019_bib57","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/gutjnl-2014-308316","article-title":"Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein","volume":"65","author":"Sautto","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.cmi.2026.08.019_bib58","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41565-019-0600-1","article-title":"Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis","volume":"15","author":"Hou","year":"2020","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.cmi.2026.08.019_bib59","doi-asserted-by":"crossref","first-page":"eadg3365","DOI":"10.1126\/sciadv.adg3365","article-title":"Surficial nano-deposition locoregionally yielding bactericidal super CAR-macrophages expedites periprosthetic osseointegration","volume":"9","author":"Li","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.cmi.2026.08.019_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph191912366","article-title":"Price and prejudice? The value of chimeric antigen receptor (CAR) T-cell therapy","volume":"19","author":"Choi","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.cmi.2026.08.019_bib61","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26004660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26004660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:29:49Z","timestamp":1788470989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26004660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":61,"alternative-id":["S1198743X26004660"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.08.019","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric antigen receptor therapy in infectious diseases: emerging applications with a focus on invasive fungal infections","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}